ArticleCell reports. Medicine2025
Enhanced formation of tertiary lymphoid structures shapes the anti-tumor microenvironment in hepatocellular carcinoma after FOLFOX-HAIC therapy.
Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative efficacy and safety of first-line treatments for advanced hepatocellular carcinoma: a Bayesian network meta-analysis.Frontiers in immunology · 2026Pooled it
- Impact of PD-1 Inhibitor Timing Relative to Locoregional Therapy on Outcomes in uHCC Treated With Lenvatinib-Based Triple Therapy.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Hepatic arterial infusion or intravenous infusion of adebrelimab, combined with bevacizumab and HAIC of the FOLFOX regimen for advanced unresectable hepatocellular carcinoma (HAIBrave-001 trial): a study protocol of a prospective, double-arm, phase II trial.Journal of gastrointestinal oncology · 2026Article
- TLS as Predictors and Targets in Neoadjuvant Chemoimmunotherapy for NSCLC.Thoracic cancer · 2026Review
- Tertiary Lymphoid Structures as Predictors of Recurrence in Colorectal Cancer: Development and Validation of a Machine Learning-Based Scoring Model.Cancer medicine · 2026Article
- Review
- Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma: a multicenter retrospective cohort study.Journal of gastroenterology · 2026Article
- Spatial co-expression and cell-cell communication inference from spatially resolved transcriptomics with CONCISE.bioRxiv : the preprint server for biology · 2026Article
- TCF1+CD4+ T cells and microglia co-orchestrate tertiary lymphoid structures to enhance prognosis and immunotherapy in non-small cell lung cancer with brain metastases.EBioMedicine · 2026Article
- Therapy-induced remodeling of the tumor immune microenvironment: Mechanistic insights and implications for immunotherapy.Chinese medical journal · 2026Review
- Chemokine-chemokine receptor axis: Emerging immunotherapeutic paradigms for solid tumor microenvironment reprogramming.Chinese medical journal · 2026Review
- Immunogenic cell death as a cornerstone for combination therapies with immune checkpoint blockade.Molecular cancer · 2026Review
- Single-cell spatial analysis identifies ID1-high endothelial cells in tertiary lymphoid structures as predictors of durable response to immunotherapy in non-small cell lung cancer.Cancer cell international · 2026Article
- Efficacy and Safety of TACE-HAIC Combined with Molecular Targeted Therapy and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Case Report: Exchange transfusion for hemolytic anemia and acute kidney injury associated with hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin in a patient with hepatocellular carcinoma.Frontiers in medicine · 2026Article
- HAIC combined with lenvatinib and tislelizumab for HCC with concurrent PVTT and pulmonary metastasis: a multicenter propensity score matching analysis.Therapeutic advances in medical oncology · 2026Article
- HAIC combined with atezolizumab and bevacizumab versus lenvatinib in advanced hepatocellular carcinoma: a multicenter propensity score matching analysis.Frontiers in oncology · 2026Article
- Concurrent expression of glucose-6-phosphate dehydrogenase and secreted phosphoprotein 1 characterizes an aggressive and immunosuppressive tumor state in hepatocellular carcinoma.Frontiers in cell and developmental biology · 2026Article
- Initiation of Tertiary Lymphoid Structures for Cancer Immunotherapy.Research (Washington, D.C.) · 2026Review
- Intratumoral Tertiary Lymphoid Structures in Hepatocellular Carcinoma: Current Evidence and Future Directions - a Narrative Review.Journal of hepatocellular carcinoma · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tertiary lymphoid structures (TLSs) emerge as crucial determinants of anti-tumor immune responses and clinical outcomes. However, their clinical significance and formation mechanisms in hepatocellular carcinoma (HCC) remain unclear. Here, we demonstrate that hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, leucovorin, and fluorouracil (FOLFOX) significantly enhances TLS formation in HCC tissues, correlating with improved therapeutic efficacy and prolonged progression-free survival in patients with HCC. Mechanistically, HAIC induces lymphotoxin β (LTβ)-expressing central memory T cell (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.